Actinium Pharmaceuti
Actinium Pharmaceuticals Announces Positive Preliminary Results from Phase 2 Trial for Actimab-A Highlighted at 59th American Society of Hematology Annual Meeting
December 11, 2017 06:30 ET | Actinium Pharmaceuticals
69% Overall Response Rate and 98% median reduction in bone marrow blasts reported with Actimab-A given at 2.0 µCi/kg/fraction as a single agent Minimal extramedullary toxicities observed; No evidence...
Actinium Pharmaceuti
Actinium Pharmaceuticals Highlights Strong Presence at 59th Annual American Society of Hematology Meeting Evidenced by Clinical Development Progress and Results Showcasing its AWE Technology Platform
November 29, 2017 07:30 ET | Actinium Pharmaceuticals
- Poster presentation to detail results from ongoing Phase 2 trial for Actimab-A, Actinium’s CD33 targeting ARC or Antibody Radio-Conjugate, designed to explore Actimab-A’s efficacy in patients newly...
Actinium Pharmaceuti
Actinium Pharmaceuticals Launches the AWE Program aka Actinium Warhead Enabling Program to Enable Collaborations Based on Its Actinium-225 Technology Platform
November 14, 2017 08:00 ET | Actinium Pharmaceuticals
- AWE Program launched post successful demonstration of Actinium’s “Biobetter” capabilities as evidenced by superior experimental results with actinium-225 labeled daratumumab when compared to...
Actinium Pharmaceuti
Actinium Pharmaceuticals to Host Webcast to Introduce New Clinical Initiative in Collaboration with Leading Hematologist Dr. Gail Roboz
November 13, 2017 07:30 ET | Actinium Pharmaceuticals
- Dr. Gail Roboz, Director of the Leukemia Program and Professor of Medicine at Weill Cornell Medical College and NewYork-Presbyterian will introduce the planned clinical initiative on the webcast  -...
Actinium Pharmaceuti
Actinium Pharmaceuticals Announces Activation of Fifteenth Clinical Trial Site in the Phase 3 SIERRA Trial for Iomab-B
October 25, 2017 07:30 ET | Actinium Pharmaceuticals
- Current clinical trial sites represent approximately one third of bone marrow transplant volume in the U.S. - Actinium to provide update on SIERRA clinical trial by year-end NEW YORK, Oct. 25,...
Actinium Pharmaceuti
Actinium Pharmaceuticals to Participate in American Society for Blood and Marrow Transplantation 2017 Corporate Council Meeting
September 20, 2017 07:30 ET | Actinium Pharmaceuticals
- Actinium is now a member of the ASBMT™ Corporate Council - Two day event focused on facilitating dialogue aimed at advancing the field of bone marrow transplantation and cellular therapy NEW YORK,...
Actinium to Present
Actinium to Present at The Rodman & Renshaw 19th Annual Global Investment Conference
September 06, 2017 16:05 ET | Actinium Pharmaceuticals
NEW YORK, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...
Actinium Pharmaceuti
Actinium Pharmaceuticals to Participate in the Oppenheimer & Co. Boston Oncology Insights Summit on August 16-17, 2017
August 09, 2017 07:30 ET | Actinium Pharmaceuticals
NEW YORK, Aug. 09, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies...
Actinium Announces C
Actinium Announces Closing of Public Offering of Common Stock and Warrants to Purchase Common Stock
August 02, 2017 16:05 ET | Actinium Pharmaceuticals
Actinium raised total gross proceeds of $16.125 million NEW YORK, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE American:ATNM) ("Actinium" or "the Company"), a...
Actinium Announces P
Actinium Announces Pricing of Public Offering of Common Stock and Warrants to Purchase Common Stock
July 28, 2017 09:10 ET | Actinium Pharmaceuticals
NEW YORK, July 28, 2017 (GLOBE NEWSWIRE) -- Actinium Pharmaceuticals, Inc. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted therapies for...